- Opens: Monday 16 November 2020
- Number of places: 1
- Duration: 36 Months
OverviewCLXL12, cancer, Nuclear factor kappa B, signalling, molecular. Cellular Basis of disease/Drug discovery
CXCL12 is a chemokine known to affect a number of important cellular events. Recent studies have implicated it in a number of disease such as cancer, arthritis and atherosclerosis. Inhibitors of the receptor for CXCL12, CXCR4, have been developed but have been found to have limited clinical success. An alternative strategy is to prevent the expression of CXCL12 as a means to inhibit its function. Using an initial CXCL12 assay screen we have uncovered a number of potential novel inhibitors. The project will assess the site and mechanism of action of these inhibitors and assess their potential as novel drugs for treatment of disease. At the same time molecular approach will allow understanding of signalling events linked to CXCL12 to be explored.
Cell culture, western blotting, imaging, gene array, FACS analysis, siRNA.
Project is suitable to be undertaken as PhD Plus
Applicants must be able to fund tuition and bench fees throughtout studies